Back to discover
Drug

Doxycycline

Approved · FDA
ClassBacterial 70S ribosome inhibitorEmerging researchLate-stage developmentSteady momentum
Also known as Acticlate, Adoxa, Alodox, Atridox+22 more

Acticlate, Adoxa, Alodox, Atridox, Avidoxy, Doryx, Doxiciclina, Doxy, Doxy Lemmon, Doxy-Caps, Doxycycline Hyclate, Mondoxyne, Monodox, Morgidox, Okebo, Oracea, Oraxyl, Periostat, Targadox, Vibra-Tabs, 6-alpha-deoxy-5-oxytetracycline, 6alpha-deoxy-5-oxytetracycline, Vibramycin, Doxycyclin, Doxycycline Monohydrate, Doxycyclinum.

8
Research papers
28
Active clinical trials
59
Protein targets
9
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

The Role of Doxycycline in the Management of Postoperative Seromas: A Pilot Study

Clinical trial2026-07-09Results expected Q2 2027 · ClinicalTrials.gov

Effects of Treatments on the Microbiome in Healthy Volunteers and Patients With Atopic Dermatitis

Clinical trial2026-07-08Results expected Q1 2027 · ClinicalTrials.gov

Guidelines of care for the management of acne vulgaris.

Research2024-01-30Journal of the American Academy of Dermatology

In vitro and in vivo evaluation of doxycycline-chondroitin sulfate/PCLmicrospheres for intraarticular treatment of osteoarthritis.

Research2014-10-28Journal of biomedical materials research. Part B, Applied biomaterials

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Doxycycline
Aliases & brands
ActiclateAdoxaAlodoxAtridoxAvidoxyDoryxDoxiciclinaDoxyDoxy LemmonDoxy-CapsDoxycycline HyclateMondoxyneMonodoxMorgidoxOkeboOraceaOraxylPeriostatTargadoxVibra-Tabs6-alpha-deoxy-5-oxytetracycline6alpha-deoxy-5-oxytetracyclineVibramycinDoxycyclinDoxycycline MonohydrateDoxycyclinum
RxNorm CUI
3640
ChEMBL ID
CHEMBL1200699
ATC codes
A01AB22J01AA02
UNII
N12000U13O
Primary mechanism
Bacterial 70S ribosome inhibitor
Regulatory jurisdictions
fda

Pharmacology & targets

59 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
INHIBITORBacterial 70S ribosome inhibitor
Matrilysin
MMP7 · P09237
INHIBITORMatrix metalloproteinase 7 inhibitor
INHIBITORMatrix metalloproteinase 8 inhibitor
Collagenase 3
MMP13 · P45452
INHIBITORMatrix metalloproteinase 13 inhibitor
INHIBITORMatrix metalloproteinase-1 inhibitor

Regulatory timeline

9 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2014-03-05
Latest approval
2017-09-28
Authorities
FDA
Total events
9
fdaU.S. Food and Drug Administration· 9 events
2026-06-12Label change
Label change: DOXYCYCLINE (ANDA204234)
Evidence ↗
2025-04-25Label change
Label change: DOXYCYCLINE (ANDA204234)
Evidence ↗
2025-04-25Label change
Label change: DOXYCYCLINE (ANDA204234)
Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Clinical trials

190 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
190
registered trials across all phases
LATEST COMPLETION 2026
28
Active studies
21
Recruiting
120
Late-stage (III+)
113
Completed
49
Discontinued
PHASE DISTRIBUTIONn = 190
Early Phase 12Phase 112Phase 1 / 28Phase 248Phase 2 / 37Phase 328Phase 454Phase N / A31

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

8 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20042024
Most influential
Recent papers
Major research themes8
Doxycycline2Acne Vulgaris1Anti-Bacterial Agents1Benzoyl Peroxide1Chondroitin Sulfates1Dermatologic Agents1Dicarboxylic Acids1Isotretinoin1
Journals, researchers & institutions
Top journals
  • American journal of veterinary research1
  • Arthritis and rheumatism1
  • Contraception1
  • Folia morphologica1
  • JAMA1
  • Journal of biomedical materials research. Part B, Applied biomaterials1
Leading researchers
  • Edelman A2
  • Jensen J2
  • Kaneshiro B2
  • Nichols M2
  • Aydin O1
  • Barbieri JS1
  • Barwijuk-Machała M1
  • Baxter BT1
Leading institutions
free-text, unnormalised
  • University of Hawaii2
  • Afyon Kocatepe University1
  • American Academy of Dermatology1
  • AO Research Institute1
  • Beth Israel Deaconess Medical Center1
  • Brigham and Women's Hospital1

Related drugs

8 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across the same disease area as Doxycycline in the shared literature.

1 shared disease1 shared paper

Studied across the same disease area as Doxycycline in the shared literature.

1 shared disease1 shared paper

Studied across the same disease area as Doxycycline in the shared literature.

1 shared disease1 shared paper

Studied across the same disease area as Doxycycline in the shared literature.

1 shared disease1 shared paper

Studied across the same disease area as Doxycycline in the shared literature.

1 shared disease1 shared paper

Studied across the same disease area as Doxycycline in the shared literature.

1 shared disease1 shared paper

Studied across the same disease area as Doxycycline in the shared literature.

1 shared disease1 shared paper

Studied across the same disease area as Doxycycline in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.